Kenji Arakawa

Prof. Kenji Arakawa

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Chemistry & Biology
Verified
Journal Article
Closed access
KAKenji Arakawa
Kenji Arakawa
FSFuminori Sugino
Fuminori Sugino
KKKazuya Kodama
Kazuya Kodama
TITatsuya Ishii
Tatsuya Ishii
HKHaruyasu Kinashi
Haruyasu Kinashi

17 November 2010 in The Journal of Antibiotics
Verified
Journal Article
Closed access
HFHeinz G Floss
Heinz G Floss
TYTin-Wein Yu
Tin-Wein Yu
KAKenji Arakawa
Kenji Arakawa

14 June 2012 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
KAKenji Arakawa
Kenji Arakawa
NTNaoto Tsuda
Naoto Tsuda
ATAkihiro Taniguchi
Akihiro Taniguchi
HKHaruyasu Kinashi
Haruyasu Kinashi

1 April 1997 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
TETadashi Eguchi
Tadashi Eguchi
KAKenji Arakawa
Kenji Arakawa
TTTakumi Terachi
Takumi Terachi
KKKatsumi Kakinuma
Katsumi Kakinuma

11 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TATamar Auerbach
Tamar Auerbach
IMInbal Mermershtain
Inbal Mermershtain
CDChen Davidovich
Chen Davidovich
ABAnat Bashan
Anat Bashan
MBMatthew Belousoff
Matthew Belousoff
AYAda Yonath
Ada Yonath
Crystallographic analysis revealed that the 17-member polyketide antibiotic lankacidin produced byStreptomyces rocheibinds at the peptidyl transferase center of the eubacterial large ribosomal subunit. Biochemical and functional studies verified this finding and showed interference with peptide bond formation. Chemical probing indicated that the macrolide lankamycin, a second antibiotic produced by the same species, binds at a neighboring site, at the ribosome exit tunnel. These two antibiotics can bind to the ribosome simultaneously and display synergy in inhibiting bacterial growth. The binding site of lankacidin and lankamycin partially overlap with the binding site of another pair of synergistic antibiotics, the streptogramins. Thus, at least two pairs of structurally dissimilar compounds have been selected in the course of evolution to act synergistically by targeting neighboring sites in the ribosome. These results underscore the importance of the corresponding ribosomal sites for development of clinically relevant synergistic antibiotics and demonstrate the utility of structural analysis for providing new directions for drug discovery.

18 February 2000 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
ODOlivier Dannenmuller
Olivier Dannenmuller
KAKenji Arakawa
Kenji Arakawa
TETadashi Eguchi
Tadashi Eguchi
KKKatsumi Kakinuma
Katsumi Kakinuma
SBSylvie Blanc
Sylvie Blanc
GOGuy Ourisson
Guy Ourisson